Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Upstart Holdings Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.04 (market cap $2.81B), while Upstart Holdings Inc trades at $22.4 (market cap $2.21B). The key difference: Dyne Therapeutics Inc. Common Stock is the larger of the two by market cap, and Upstart Holdings Inc is more actively traded (5,011,542 versus 2,195,902). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Upstart Holdings Inc for 39 Days on average.
| DYN | UPST | |
|---|---|---|
Market Cap | $2.81B | $2.21B |
Volume | 2,195,902 | 5,011,542 |
Sector | Health | Financials |
52-Week High | $26.78 | $52.74 |
52-Week Low | $14.60 | $22.74 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $2.13B | $3.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
UPST trades at $23.83, up 0.34% on the day but remains in a bearish technical trend. The company achieved profitability in 2025 with $1.02B revenue and $53.6M net income, though recent quarters show earnings misses. Analyst consensus is mixed with a $38.13 price target, while technical indicators signal caution with bearish moving averages and neutral oscillators.
The outlook balances AI-driven lending growth potential against execution risks and volatile cash flows. Key opportunities include expanding partnerships and securitization deals, while risks involve credit market sensitivity and rising debt levels. The stock trades at a premium valuation despite recent operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
